Ziwig
Ziwig is a Lyon-based French biotech company that has developed Ziwig Endotest®, the first saliva-based in vitro diagnostic for endometriosis, using proprietary microRNA analysis combined with next-generation sequencing and AI. The company serves women aged 18-43 with suspected endometriosis symptoms through gynecologists, medical laboratories, and the Ziwig Care network, with commercial launch in France from 2025.
- Company typePrivate
- Founded2020
- HeadquartersLyon, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Ziwig does
Ziwig is a French biotech company founded in 2019 and headquartered in Lyon, France, specializing in women's health diagnostics through salivary RNA analysis combined with artificial intelligence. The company's flagship product, Ziwig Endotest®, is the first in vitro diagnostic medical device for endometriosis using a saliva sample, employing a proprietary 109-miRNA signature analyzed via next-generation sequencing (NGS) and interpreted by machine learning algorithms. The diagnostic claims sensitivity above 97% and specificity above 93%, with results available in days rather than the typical 7-10 year diagnostic delay associated with endometriosis. Ziwig operates a vertically integrated ecosystem spanning Ziwig R&D (a research laboratory at the Institut du Cerveau, Pitié-Salpêtrière Hospital in Paris), Ziwig Lab (an industrial production facility in Tercis-les-Bains capable of processing 4,500 tests per week via the world's only fully robotized salivary RNA extraction line), Ziwig Connect (a digital platform for health data integration), and Ziwig Care (a healthcare professional network).
The company's business model centers on B2B2C distribution of Ziwig Endotest® as a prescription-only in vitro diagnostic, sold through medical laboratories and gynecologists, with pricing not publicly disclosed and conducted on a quote basis. Commercial launch in France is scheduled for 2025 following French National Health Authority (HAS) early access validation and CE certification. The company also offers customized sequencing solutions to healthcare establishments, public health institutions, and biopharmaceutical firms through Ziwig Lab. Revenue had not commenced prior to 2025 per company disclosures. Distribution combines direct enterprise sales via the Ziwig Care network in France with international channel partners and clinical trial-driven market entry across Europe (Belgium, Switzerland), North Africa (Tunisia), and broader international geographies via the GYNARN study spanning 10 countries.
Ziwig is led by founder and Chairman Yahya El Mir (a chemist and entrepreneur) and CEO Julien Perrier (appointed 2025 with international pharmaceutical and biotech experience). The company has secured strategic technology partnerships with Revvity, Illumina, and Qiagen for production automation and sequencing platforms, alongside research partnerships with the Institut du Cerveau, CNGOF, and SIFEM. Government backing comes via the France 2030 investment program. The technology has earned notable recognition including Prix Galien International 2024 for Best Medical Technology, Prix Galien National 2022, EY Entrepreneur of the Year Auvergne-Rhône-Alpes 2024, and publication in NEJM Evidence (2023 and 2025). The clinical pipeline extends beyond endometriosis toward gynecological cancers and neurodegenerative diseases, leveraging the same salivary RNA platform.
Ziwig firmographics
Firmographics- Name
- Ziwig
- Legal name
- ZIWIG
- Website
- https://ziwig.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ziwig is a Lyon-based French biotech company that has developed Ziwig Endotest®, the first saliva-based in vitro diagnostic for endometriosis, using proprietary microRNA analysis combined with next-generation sequencing and AI. The company serves women aged 18-43 with suspected endometriosis symptoms through gynecologists, medical laboratories, and the Ziwig Care network, with commercial launch in France from 2025.
- Ownership category
- akta.pro rank
Ziwig industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Ziwig is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Ziwig business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Ziwig Endotest Diagnostic Sales: Revenue from the sale of Ziwig Endotest, an in vitro diagnostic medical device for endometriosis diagnosis using saliva samples. The test is available by medical prescription only and is performed in laboratories. Revenue projections set to begin in 2025.
- Customized Sequencing Solutions: Ziwig Lab offers customized sequencing solutions to healthcare establishments, public health institutions and companies in the biopharmaceutical sector, meeting challenges of quality, reproducibility, reduced costs and rapid turnaround.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Ziwig Endotest diagnostic test for endometriosis |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
Ziwig product offering
Product offeringCore offering
Ziwig develops and commercializes Ziwig Endotest®, a CE-marked in vitro diagnostic medical device that diagnoses endometriosis from a saliva sample using high-throughput sequencing of salivary microRNAs combined with AI modeling. The company operates an integrated ecosystem spanning an R&D laboratory at Institut du Cerveau in Paris, an industrial production facility (Ziwig Lab) in Tercis-les-Bains, and a digital platform (Ziwig Connect) supporting clinical research, production, and care coordination.
Product overview
Ziwig offers a unified diagnostic ecosystem centered on Ziwig Endotest®, an in vitro diagnostic device for endometriosis diagnosis using salivary RNA analysis combined with AI. The portfolio includes Ziwig R&D (research laboratory at Institut du Cerveau in Paris) for fundamental molecular biology research, Ziwig Lab (industrial production facility in Tercis-les-Bains) for scalable manufacturing processing up to 4,500 tests weekly, Ziwig Connect (digital platform) for integrating health data across research, clinical trials, and patient services, and Ziwig Care (healthcare coordination network) for connecting patients with endometriosis care facilities.
Differentiator
Problem solved
Functional benefit
Brands
- Ziwig Endotest®: Salivary diagnostic test for endometriosis using miRNA analysis and artificial intelligence
- Ziwig Connect
- Ziwig Lab
- Ziwig R&D
- Ziwig Care
- Ziwig Foundation
- Endo'Lives
- Precision for Women
Products and services
- Ziwig Endotest® CE-marked in vitro diagnostic medical device for endometriosis that uses a saliva sample analyzed via high-throughput sequencing of salivary microRNAs combined with AI to deliver diagnostic results in a few days, with sensitivity above 97% and specificity above 93%. It is reserved for professional healthcare use, prescribed by clinicians, and performed in partner laboratories.
- Customized Sequencing Solutions (Ziwig Lab) Customized salivary RNA sequencing services offered to healthcare establishments, public health institutions, and biopharmaceutical companies via Ziwig Lab, leveraging a fully robotized extraction line and NGS platform with capacity of up to 4,500 tests per week to meet quality, reproducibility, cost, and turnaround-time requirements.
Quantifiable outcome
- Sensitivity >97%, Specificity >93%
- +3 more outcomes
Companies that use Ziwig
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Ziwig technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Ziwig partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- RevvitycoreStrategic technology partnership for the fully robotized salivary RNA analysis chain. Revvity provides technology integration at every stage of the production process, ensuring optimal quality, reproducibility, flexibility and efficiency.
- IlluminacorePartnership for next-generation sequencing technology integration. Illumina provides the sequencing platform used in the diagnostic process, enabling high-throughput RNA analysis with precision.
- QiagencoreIndustrial reference partner for diagnostic production. Qiagen contributes to the production standards of Ziwig's diagnostics ensuring quality and reliability.
- Institut du Cerveau (Brain Institute)coreHome to Ziwig R&D laboratory. The Brain Institute at Pitié-Salpêtrière Hospital provides the research facility for fundamental research in molecular biology and next-generation sequencing. Critical contribution to R&D activities.
- ProjectEndo.orgminorPartnership for distribution of the Below the Belt documentary in France. Ziwig Foundation partners with ProjectEndo.org to support awareness and education about endometriosis through the documentary.
- Endomind FranceminorPatient association representing women with endometriosis in France. Partner in awareness initiatives and patient advocacy for endometriosis awareness and care improvement.
- Fibrome Info FranceminorPatient association dedicated to uterine fibroids, the number one disease affecting women. Partner in women's health education and awareness initiatives.
- Collège National des Gynécologues Obstétriciens (CNGOF)coreOfficial representative organization of obstetricians gynecologists in France. Provides scientific and operational expertise while respecting total independence and ethical requirements. Partner in improving care pathways and promoting innovative medical practices.
- Société d'Imagerie de la Femme (SIFEM)coreProfessional society for women's imaging. Contributes scientific and operational expertise in endometriosis diagnosis through imaging, working to improve care pathways.
- Amazon Web Services (AWS)coreCloud infrastructure provider certified as Health Data Host (Hébergeur de Données de Santé - HDS) for secure hosting of health data. Provides secure data storage compliant with French health data regulations.
- Ziwig LabcoreIndustrial partner laboratory located in Tercis-les-Bains, Landes. First molecular medical biology laboratory specializing in salivary RNA analysis with fully robotized production line. Processes up to 4,500 tests per week.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Ziwig competitors and assessment
Company assessmentDirect peers
- dotLab: dotLab develops molecular diagnostics for endometriosis, including a blood-based microRNA biomarker test (dotEndo). It is the closest direct competitor to Ziwig Endotest®, targeting the same patient population with a similar non-invasive molecular approach.
Broad incumbents
- Hologic: Hologic is a large women's health diagnostics and medical device company offering a broad portfolio including molecular diagnostics, imaging, and surgical solutions. Its scale and existing gynecology sales channels make it a likely competitive incumbent if endometriosis molecular diagnostics scale.
- Myriad Genetics: Myriad Genetics is an established molecular diagnostics company known for hereditary cancer and women's health tests. Its commercial infrastructure and payer relationships in women's health position it as a broad incumbent relevant to Ziwig's pipeline expansion beyond endometriosis.
- Veracyte: Veracyte is a genomic diagnostics company specializing in molecular tests across urology, thyroid, and women's health. Its expertise in RNA-based diagnostics and securing reimbursement for novel molecular tests makes it a directly relevant broad incumbent peer.
- Natera: Natera is a molecular diagnostics company with strong presence in reproductive health (non-invasive prenatal testing, carrier screening, oncology). Its women's health commercial reach and molecular diagnostic expertise make it a comparable broad incumbent.
- ReproSource (now part of Quest Diagnostics): ReproSource, integrated into Quest Diagnostics, specialized in reproductive medicine diagnostics. Quest's national clinical laboratory network and reproductive health offerings provide broad market reach for women's health molecular diagnostics.
- CooperSurgical: CooperSurgical is a major women's health medical device and fertility company offering diagnostic, surgical, and ART products. Its strong gynecology channel relationships make it strategically relevant as Ziwig scales commercial access to practitioners.
Emerging players
- MDNA Life Sciences: MDNA Life Sciences develops molecular diagnostic tests based on mitochondrial DNA biomarkers, with applications in women's health including endometriosis. It is an emerging player addressing similar unmet diagnostic needs via novel molecular approaches.
Others
- Eurofins Genomics: Eurofins Genomics is a global genomics services provider offering sequencing, genotyping, and molecular biology services. As an established CDMO/service provider with deep European footprint, it represents a potential partner or competitive sequencing-services alternative to Ziwig Lab.
- Illumina: Illumina is a core technology partner of Ziwig for NGS platforms and could be considered both an enabler and a competitive threat if it vertically integrates into clinical diagnostics for endometriosis. Its dominance in sequencing infrastructure is directly relevant to Ziwig's production economics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ziwig social profiles
Digital presenceZiwig compliance and trust
Trust signalCompliance4 records
Ziwig financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ziwig leadership team
Management profileNumber of profiles
Profiles3 records
Ziwig subsidiaries and ownership
Company hierarchySubsidiaries2 records
Ziwig funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ziwig M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ziwig
What does Ziwig do?
Ziwig develops and commercializes Ziwig Endotest®, a CE-marked in vitro diagnostic medical device that diagnoses endometriosis from a saliva sample using high-throughput sequencing of salivary microRNAs combined with AI modeling. The company operates an integrated ecosystem spanning an R&D laboratory at Institut du Cerveau in Paris, an industrial production facility (Ziwig Lab) in Tercis-les-Bains, and a digital platform (Ziwig Connect) supporting clinical research, production, and care coordination.
Is Ziwig a public or private company?
Ziwig is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Ziwig founded?
Ziwig was founded in 2020. It employs 11 to 50 people.
Where is Ziwig based?
Ziwig is headquartered in Lyon, France, in the Europe region.
How does Ziwig make money?
Two revenue lines are on record. Ziwig Endotest Diagnostic Sales are the primary driver. The others are customized Sequencing Solutions.
Who are Ziwig's main competitors?
dotLab is listed as a direct peer. Broad incumbents are Hologic, Myriad Genetics, Veracyte, Natera, ReproSource (now part of Quest Diagnostics) and CooperSurgical. MDNA Life Sciences is listed as an emerging player. Others are Eurofins Genomics and Illumina.
Does Ziwig have an API?
No public API is recorded for Ziwig.
What industry is Ziwig in?
Ziwig's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 3391 and its SIC code is 2835.